17(ss)-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen

被引：0
|
作者：
Kallstrom, A-C
Salme, R.
Ryden, L.
Gunnarsson, C.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborg Hosp, Helsingborg, Sweden
[2] Univ Hosp, Linkoping, Sweden
[3] Univ Lund Hosp, S-22185 Lund, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S84 / S85
页数：2
相关论文
共 50 条
  • [1] 17β-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
    Kallstrom, Ann-Christine
    Salme, Rebecka
    Ryden, Lisa
    Nordenskjold, Bo
    Jonsson, Per-Ebbe
    Stal, Olle
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (05) : 892 - 900
  • [2] 17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
    Sivik, Tove
    Gunnarsson, Cecilia
    Fornander, Tommy
    Nordenskjold, Bo
    Skoog, Lambert
    Stal, Olle
    Jansson, Agneta
    PLOS ONE, 2012, 7 (07):
  • [3] Quantitative measurement of EGFR is a predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer
    Ryden, L.
    Giltnane, J.
    Cregger, M.
    Jirstrom, K.
    Bendahl, P.
    Rimm, D.
    BREAST, 2007, 16 : S29 - S29
  • [4] Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor -: Positive premenopausal breast cancer
    Giltnane, Jennifer M.
    Ryden, Lisa
    Cregger, Melissa
    Bendahl, Par-Ola
    Jirstrom, Karin
    Rimm, David L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3007 - 3014
  • [5] Impairment of the executive attention network in premenopausal women with hormone receptor-positive breast cancer treated with tamoxifen
    Chen, Xingui
    Li, Jingjing
    Zhang, Jingjie
    He, Xiaoxuan
    Zhu, Chunyan
    Zhang, Lei
    Hu, Xinglong
    Wang, Kai
    PSYCHONEUROENDOCRINOLOGY, 2017, 75 : 116 - 123
  • [6] 17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer
    Day, Joanna M.
    Foster, Paul A.
    Tutill, Helena J.
    Parsons, Michael F. C.
    Newman, Simon P.
    Chander, Surinder K.
    Allan, Gillian M.
    Lawrence, Harshani R.
    Vicker, Nigel
    Potter, Barry V. L.
    Reed, Michael J.
    Purohit, Atul
    INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (09) : 1931 - 1940
  • [7] 17β-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer
    Oduwole, OO
    Li, Y
    Isomaa, VV
    Mäntyniemi, A
    Pulkka, AE
    Soini, Y
    Vihko, PT
    CANCER RESEARCH, 2004, 64 (20) : 7604 - 7609
  • [8] HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
    Lisa Rydén
    Göran Landberg
    Olle Stål
    Bo Nordenskjöld
    Mårten Fernö
    Pär-Ola Bendahl
    Breast Cancer Research and Treatment, 2008, 109 : 351 - 357
  • [9] HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
    Ryden, Lisa
    Landberg, Goran
    Stal, Olle
    Nordenskjold, Bo
    Ferno, Marten
    Bendahl, Par-Ola
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 351 - 357
  • [10] HER2 status adds prognostic, but not tamoxifen treatment predictive, information in hormone receptor positive premenopausal primary breast cancer
    Ryden, L.
    Ferno, M.
    Landberg, G.
    Bendahl, P. O.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S63 - S64
12345